LO CAPUTO, Sergio
LO CAPUTO, Sergio
Dipartimento di Scienze Mediche e Chirurgiche
. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.
2005-01-01 Torti, C; Lapadula, G; Casari, S; Puoti, M; Nelson, M; Quiros-Roldan, E; Bella, D; Pastore, G; Ladisa, N; Minoli, L; Sotgiu, G; Mazzotta, F; Lo Caputo, S; Di Perri, G; Filice, G; Tinelli, C; Carosi, G; EPOKA-MASTER Study, Group.
. Reduced community viral load does not coincide with a reduction in the rate of new HIV diagnoses and recent infections: data from a region of southern Italy
2017-01-01 Monno, L; Saracino, A; Scudeller, L; Santoro, C; Brindicci, G; Punzi, G; Lagioia, A; Lo Caputo, S; Angarano, G.
2Apolipoprotein B mRNA–Editing Enzyme, Catalytic Polypeptide–Like 3G: A PossibleRole in the Resistance to HIV of HIV-1 Exposed Seronegative Individuals
2007-01-01 Mara, Biasin; Luca, Piacentini; Lo Caputo, S; Yasuyoshi, Kanari; Giuliana, Magri; Daria, Trabattoni; Valentina, Naddeo; Lucia, Lopalco; Alberto, Clivio; Eugenio, Cesana; Francesca, Fasano; Cristina, Bergamaschi; Francesco, Mazzotta; Masaaki, Miyazawa; and Mario, Clerici
96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience
2012-01-01 Capetti, A; Landonio, S; Meraviglia, P; Di Biagio, A; Lo Caputo, S; Sterrantino, G; Ammassari, A; Menzaghi, B; Franzetti, M; De Socio, Gv; Pellicanò, G; Mazzotta, E; Soria, A; Meschiari, M; Trezzi, M; Sasset, L; Celesia, Bm; Zucchi, P; Melzi, S; Ricci, E; Rizzardini, G
A 6-amino acid insertion/deletion polymorphism in the mucin domain of TIM-1 confers protections against HIV-1 infection
2017-01-01 Biasin, M; Sironi, M; Saulle, I; Pontremoli, C; Garziano, M; Cagliani, R; Trabattoni, D; Lo Caputo, S; Vichi, F; Mazzotta, F; Forni, D; Riva, S; Aguilar-Jimenez, W; Cedeño, S; Sanchez, J; Brander, C; Zapata, W; Rugeles, Mt; Clerici, M.
A common polymorphism in TLR3 confers natural resistance to HIV-1 infection
2012-01-01 Sironi, M; Biasin, M; Cagliani, R; Forni, D; De Luca, M; Saulle, I; Lo Caputo, S; Mazzotta, F; Macías, J; Pineda, Ja; Caruz, A; Clerici, M
A comprehensive development agenda on tenofovir alafenamide in clinical practice
2018-01-01 Di Biagio, A.; Riccardi, N.; Rusconi, S.; Guaraldi, G.; Borderi, M.; De Luca, A.; Gianotti, N.; Lo Caputo, S.; Maggi, P.; Maserati, R.; Maggiolo, F.
A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice
2018-01-01 Di Biagio, Antonio; Riccardi, Niccolò; Rusconi, Stefano; Guaraldi, Giovanni; Borderi, Marco; De Luca, Andrea; Gianotti, Nicola; Lo Caputo, Sergio; Maggi, Paolo; Maserati, Renato; Maggiolo, Franco
A positively selected APOBEC3H haplotype is associated with natural resistance to HIV-1 infection
2011-01-01 Cagliani, R; Riva, S; Fumagalli, M; Biasin, M; Lo Caputo, S; Mazzotta, F; Piacentini, L; Pozzoli, U; Bresolin, N; Clerici, M; Sironi, M
A Randomized Controlled Trial to Evaluate Antiretroviral Salvage Therapy Guided by Rules-Based or Phenotype-Driven HIV-1 Genotypic Drug-Resistance Interpretation With or Without Concentration-Controlled Intervention: The Resistance and Dosage Adapted Regimens (RADAR) Study
2005-01-01 Carlo, Torti; Eugenia, Quiros‐roldan; Mario, Regazzi; Andrea De, Luca; Francesco, Mazzotta; Andrea, Antinori; Nicoletta, Ladisa; Valeria, Micheli; Anna, Orani; Andrea, Patroni; Paola, Villani; Lo Caputo, S; Francesca, Moretti; Simona Di, Giambenedetto; Filippo, Castelnuovo; Paolo, Maggi; Carmine, Tinelli; Giampiero, Carosi; and the RADAR-MASTER Study, Group
A role for mucosal immunity in resistance to HIV infection
1999-01-01 Clerici, M; Salvi, A; Trabattoni, D; Lo Caputo, S; Semplici, F; Biasin, M; Ble, C; Meacci, F; Romeo, C; Piconi, S; Mazzotta, F; Villa, Ml; Mazzoli, S
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort
2017-01-01 d'Arminio Monforte, A; Cozzi-Lepri, A; Ceccherini-Silberstein, F; De Luca, A; Lo Caputo, S; Castagna, A; Mussini, C; Cingolani, A; Tavelli, A; Shanyinde, M; Gori, A; Girardi, E; Andreoni, M; Antinori, A; Puoti, M; Icona Foundation and HepaIcona Study, Group
An evolutionary analysis of antigen processing and presentation across different timescales reveals pervasive selection.
2014-01-01 Forni, D; Cagliani, R; Tresoldi, C; Pozzoli, U; De Gioia, L; Filippi, G; Riva, S; Menozzi, G; Colleoni, M; Biasin, M; Lo Caputo, S; Mazzotta, F; Comi, Gp; Bresolin, N; Clerici, M; Sironi, M
An intricate case of multidrug resistant Plasmodium falciparum isolate imported from Cambodia.
2017-01-01 Dell'Acqua, R; Fabrizio, C; Di Gennaro, F; Lo Caputo, S; Saracino, A; Menegon, M; L'Episcopia, M; Severini, C; Monno, L; Castelli, F; Angarano, G
Anti-nef antibodies and other predictors of disease progression in HIV-1 seropositive injecting drug users
1992-01-01 Rezza, G; Titti, F; Pezzotti, P; Sernicola, L; Lo Caputo, S; Angarano, G; Lazzarin, A; Sinicco, A; Rossi, Gb; Verani, P.
Apulian infectious diseases network: survey on the prevalence of delta infection among chronic HBV carriers in Apulia
2023-01-01 Fasano, Massimo; Milella, Michele; Carbonara, Sergio; Tundo, Paolo; Minniti, Salvatore; Buccoliero, Giovanni; Maci, Anna Maria; Lo Caputo, Sergio; Santantonio, Teresa Antonia
Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection
2015-01-01 Herrero, R; Real, Lm; Rivero-Juárez, A; Pineda, Ja; Camacho, Á; Macías, J; Laplana, M; Konieczny, P; Márquez, Fj; Souto, Jc; Soria, Jm; Saulle, I; Lo Caputo, S; Biasin, M; Rivero, A; Fibla, J; Caruz, A
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial
2016-01-01 Galli, Laura; Spagnuolo, Vincenzo; Bigoloni, Alba; D'Arminio Monforte, Antonella; Montella, Francesco; Antinori, Andrea; Di Biagio, Antonio; Rusconi, Stefano; Guaraldi, Giovanni; Di Giambenedetto, Simona; Borderi, Marco; Gibellini, Davide; Caramatti, Giada; Lazzarin, Adriano; Castagna, Antonella; LO CAPUTO, Sergio
Baricitinib: A chance to treat COVID-19?
2020-01-01 Lo Caputo, S.; Corso, G.; Clerici, M.; Santantonio, T. A.
Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe
2012-01-01 Nakagawa, Fumiyo; Lodwick, Rebecca; Costagliola, Dominique; van Sighem, Ard; Torti, Carlo; Podzamczer, Daniel; Mocroft, Amanda; Ledergerber, Bruno; Dorrucci, Maria; Cozzi-Lepri, Alessandra; Jansen, Klaus; Masquelier, Bernard; García, Federico; De Wit, Stephane; Stephan, Christoph; Obel, Niels; Fätkenhaeuer, Gerd; Castagna, Antonella; Sambatakou, Helen; Mussini, Cristina; Ghosn, Jade; Zangerle, Robert; Duval, Xavier; Meyer, Laurence; Perez-Hoyos, Santiago; Fabre Colin, Céline; Kjaer, Jesper; Chene, Genevieve; Grarup, Jesper; Phillips, Andrew; LO CAPUTO, Sergio
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| . Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. | 1-gen-2005 | Torti, C; Lapadula, G; Casari, S; Puoti, M; Nelson, M; Quiros-Roldan, E; Bella, D; Pastore, G; Ladisa, N; Minoli, L; Sotgiu, G; Mazzotta, F; Lo Caputo, S; Di Perri, G; Filice, G; Tinelli, C; Carosi, G; EPOKA-MASTER Study, Group. | |
| . Reduced community viral load does not coincide with a reduction in the rate of new HIV diagnoses and recent infections: data from a region of southern Italy | 1-gen-2017 | Monno, L; Saracino, A; Scudeller, L; Santoro, C; Brindicci, G; Punzi, G; Lagioia, A; Lo Caputo, S; Angarano, G. | |
| 2Apolipoprotein B mRNA–Editing Enzyme, Catalytic Polypeptide–Like 3G: A PossibleRole in the Resistance to HIV of HIV-1 Exposed Seronegative Individuals | 1-gen-2007 | Mara, Biasin; Luca, Piacentini; Lo Caputo, S; Yasuyoshi, Kanari; Giuliana, Magri; Daria, Trabattoni; Valentina, Naddeo; Lucia, Lopalco; Alberto, Clivio; Eugenio, Cesana; Francesca, Fasano; Cristina, Bergamaschi; Francesco, Mazzotta; Masaaki, Miyazawa; and Mario, Clerici | |
| 96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience | 1-gen-2012 | Capetti, A; Landonio, S; Meraviglia, P; Di Biagio, A; Lo Caputo, S; Sterrantino, G; Ammassari, A; Menzaghi, B; Franzetti, M; De Socio, Gv; Pellicanò, G; Mazzotta, E; Soria, A; Meschiari, M; Trezzi, M; Sasset, L; Celesia, Bm; Zucchi, P; Melzi, S; Ricci, E; Rizzardini, G | |
| A 6-amino acid insertion/deletion polymorphism in the mucin domain of TIM-1 confers protections against HIV-1 infection | 1-gen-2017 | Biasin, M; Sironi, M; Saulle, I; Pontremoli, C; Garziano, M; Cagliani, R; Trabattoni, D; Lo Caputo, S; Vichi, F; Mazzotta, F; Forni, D; Riva, S; Aguilar-Jimenez, W; Cedeño, S; Sanchez, J; Brander, C; Zapata, W; Rugeles, Mt; Clerici, M. | |
| A common polymorphism in TLR3 confers natural resistance to HIV-1 infection | 1-gen-2012 | Sironi, M; Biasin, M; Cagliani, R; Forni, D; De Luca, M; Saulle, I; Lo Caputo, S; Mazzotta, F; Macías, J; Pineda, Ja; Caruz, A; Clerici, M | |
| A comprehensive development agenda on tenofovir alafenamide in clinical practice | 1-gen-2018 | Di Biagio, A.; Riccardi, N.; Rusconi, S.; Guaraldi, G.; Borderi, M.; De Luca, A.; Gianotti, N.; Lo Caputo, S.; Maggi, P.; Maserati, R.; Maggiolo, F. | |
| A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice | 1-gen-2018 | Di Biagio, Antonio; Riccardi, Niccolò; Rusconi, Stefano; Guaraldi, Giovanni; Borderi, Marco; De Luca, Andrea; Gianotti, Nicola; Lo Caputo, Sergio; Maggi, Paolo; Maserati, Renato; Maggiolo, Franco | |
| A positively selected APOBEC3H haplotype is associated with natural resistance to HIV-1 infection | 1-gen-2011 | Cagliani, R; Riva, S; Fumagalli, M; Biasin, M; Lo Caputo, S; Mazzotta, F; Piacentini, L; Pozzoli, U; Bresolin, N; Clerici, M; Sironi, M | |
| A Randomized Controlled Trial to Evaluate Antiretroviral Salvage Therapy Guided by Rules-Based or Phenotype-Driven HIV-1 Genotypic Drug-Resistance Interpretation With or Without Concentration-Controlled Intervention: The Resistance and Dosage Adapted Regimens (RADAR) Study | 1-gen-2005 | Carlo, Torti; Eugenia, Quiros‐roldan; Mario, Regazzi; Andrea De, Luca; Francesco, Mazzotta; Andrea, Antinori; Nicoletta, Ladisa; Valeria, Micheli; Anna, Orani; Andrea, Patroni; Paola, Villani; Lo Caputo, S; Francesca, Moretti; Simona Di, Giambenedetto; Filippo, Castelnuovo; Paolo, Maggi; Carmine, Tinelli; Giampiero, Carosi; and the RADAR-MASTER Study, Group | |
| A role for mucosal immunity in resistance to HIV infection | 1-gen-1999 | Clerici, M; Salvi, A; Trabattoni, D; Lo Caputo, S; Semplici, F; Biasin, M; Ble, C; Meacci, F; Romeo, C; Piconi, S; Mazzotta, F; Villa, Ml; Mazzoli, S | |
| Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort | 1-gen-2017 | d'Arminio Monforte, A; Cozzi-Lepri, A; Ceccherini-Silberstein, F; De Luca, A; Lo Caputo, S; Castagna, A; Mussini, C; Cingolani, A; Tavelli, A; Shanyinde, M; Gori, A; Girardi, E; Andreoni, M; Antinori, A; Puoti, M; Icona Foundation and HepaIcona Study, Group | |
| An evolutionary analysis of antigen processing and presentation across different timescales reveals pervasive selection. | 1-gen-2014 | Forni, D; Cagliani, R; Tresoldi, C; Pozzoli, U; De Gioia, L; Filippi, G; Riva, S; Menozzi, G; Colleoni, M; Biasin, M; Lo Caputo, S; Mazzotta, F; Comi, Gp; Bresolin, N; Clerici, M; Sironi, M | |
| An intricate case of multidrug resistant Plasmodium falciparum isolate imported from Cambodia. | 1-gen-2017 | Dell'Acqua, R; Fabrizio, C; Di Gennaro, F; Lo Caputo, S; Saracino, A; Menegon, M; L'Episcopia, M; Severini, C; Monno, L; Castelli, F; Angarano, G | |
| Anti-nef antibodies and other predictors of disease progression in HIV-1 seropositive injecting drug users | 1-gen-1992 | Rezza, G; Titti, F; Pezzotti, P; Sernicola, L; Lo Caputo, S; Angarano, G; Lazzarin, A; Sinicco, A; Rossi, Gb; Verani, P. | |
| Apulian infectious diseases network: survey on the prevalence of delta infection among chronic HBV carriers in Apulia | 1-gen-2023 | Fasano, Massimo; Milella, Michele; Carbonara, Sergio; Tundo, Paolo; Minniti, Salvatore; Buccoliero, Giovanni; Maci, Anna Maria; Lo Caputo, Sergio; Santantonio, Teresa Antonia | |
| Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection | 1-gen-2015 | Herrero, R; Real, Lm; Rivero-Juárez, A; Pineda, Ja; Camacho, Á; Macías, J; Laplana, M; Konieczny, P; Márquez, Fj; Souto, Jc; Soria, Jm; Saulle, I; Lo Caputo, S; Biasin, M; Rivero, A; Fibla, J; Caruz, A | |
| Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial | 1-gen-2016 | Galli, Laura; Spagnuolo, Vincenzo; Bigoloni, Alba; D'Arminio Monforte, Antonella; Montella, Francesco; Antinori, Andrea; Di Biagio, Antonio; Rusconi, Stefano; Guaraldi, Giovanni; Di Giambenedetto, Simona; Borderi, Marco; Gibellini, Davide; Caramatti, Giada; Lazzarin, Adriano; Castagna, Antonella; LO CAPUTO, Sergio | |
| Baricitinib: A chance to treat COVID-19? | 1-gen-2020 | Lo Caputo, S.; Corso, G.; Clerici, M.; Santantonio, T. A. | |
| Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe | 1-gen-2012 | Nakagawa, Fumiyo; Lodwick, Rebecca; Costagliola, Dominique; van Sighem, Ard; Torti, Carlo; Podzamczer, Daniel; Mocroft, Amanda; Ledergerber, Bruno; Dorrucci, Maria; Cozzi-Lepri, Alessandra; Jansen, Klaus; Masquelier, Bernard; García, Federico; De Wit, Stephane; Stephan, Christoph; Obel, Niels; Fätkenhaeuer, Gerd; Castagna, Antonella; Sambatakou, Helen; Mussini, Cristina; Ghosn, Jade; Zangerle, Robert; Duval, Xavier; Meyer, Laurence; Perez-Hoyos, Santiago; Fabre Colin, Céline; Kjaer, Jesper; Chene, Genevieve; Grarup, Jesper; Phillips, Andrew; LO CAPUTO, Sergio |